Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Endo Pharmaceuticals, a specialty pharmaceutical company, has completed its acquisition of Indevus Pharmaceuticals, a developer of products to treat conditions in urology and endocrinology.
Subscribe to our email newsletter
Endo has acquired Indevus through a tender offer and subsequent merger upon which Indevus became a wholly owned subsidiary of Endo.
The common stock of Indevus ceased trading at market close on March 23, 2009 and has been converted into the right to receive $4.50 per Indevus share in cash and up to an additional $3 per share in cash upon achievement of certain regulatory and sales milestones.